Elevated NLR May Be a Feature of Pediatric Brain Cancer Patients

Michal Yalon 1†, Amos Toren 1-2†, Dina Jabarin 2, Edna Fadida 3, Shlomi Constantini 3 and Ruty Mehrian-Shai 1*

1 Pediatric Hemato-Oncology, Edmond and Lilly Safra Children’s Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel, 2 The Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel, 3 Department of Pediatric Neurosurgery, Dana Children’s Hospital, Tel-Aviv-Sourasky Medical Center, Tel Aviv, Israel

Pediatric brain tumors are the most common solid tumor type and the leading cause of cancer-related death in children. The immune system plays an important role in cancer pathogenesis and in the response to immunotherapy treatments. T lymphocytes are key elements for the response of the immune system to cancer cells and have been associated with prognosis of different cancers. Neutrophils on the other hand, which secrete pro-angiogenic and anti-apoptotic factors, enhance the ability of tumor cells to grow and develop into metastases. We conducted a retrospective study of 120 pediatric brain cancer patients and 171 elective pediatric patients hospitalized in Dana Children’s Hospital and Sheba Medical Center. Data on age, sex, treatment, lymphocyte, neutrophil, and monocyte count were collected from routinely performed preoperative blood tests. Neutrophil-to-lymphocyte ratio (NLR), and the lymphocyte-to-monocyte ratio (LMR) were calculated and significance was determined by paired T test. \( p < 0.05 \) was considered as statistically significant. NLR was significantly higher in the pediatric brain cancer patients. The high NLR in pediatric brain cancer patients is the result of a combination of low lymphocytes and high neutrophils. Both of these factors can have a role in cancer development and propagation and also in response to therapy.

Keywords: pediatric brain cancer, neutrophils, lymphocytes, NLR, LMR

INTRODUCTION

Pediatric brain tumors are the most common solid tumor type and the leading cause of cancer-related deaths in children aged 0–14 years (1). There is increasing evidence that malfunction of immune system may contribute to tumor development. Failure to eliminate tumor cells or keeping the tumor cells in a dormant state by the immune system are included in the “hallmarks of cancer” (2). Understanding these underlying mechanisms has provided a basis for the development of new immunotherapies against tumors.

Lymphocytes have, among others, an anti-tumor effect (3). T lymphocytes are key elements to eliminate cancer cells and their dysfunction have been associated with development of cancer (4) and prognosis for several cancer types. Neutrophils and monocytes on the other hand, may promote tumor progression (5). Neutrophils which secrete pro-angiogenic and anti-apoptotic factors, enhance the ability of tumor cells to grow and develop into metastases (6). Elevated numbers of neutrophils in the peripheral blood is associated with poor outcome in several types of cancers (7). Tumor-associated neutrophils can acquire a pro-tumor phenotype, supporting tumor growth, and suppressing the antitumor
immune response (8). Myeloid-derived suppressor cells (MDSC) which are closely related to neutrophils and monocytes (9) play a major role in suppression of T cells (10, 11). Not only are levels of MDSC increased in the blood of patients with cancer, MDSC frequencies correlate to clinical cancer stage in several cancers including bladder cancer (12) and breast cancer (13).

Neutrophils, lymphocytes and monocytes have prognostic value in patients with a variety of common solid tumors (14). These patients are characterized by an increase in circulating neutrophil levels accompanied by a fall in circulating lymphocyte levels thus the neutrophil to lymphocyte ratio (NLR) is increased. In general, the blood NLR is high in patients with more advanced or aggressive cancers (15) and correlates with poor survival of patients with many solid tumors (16, 17).

Lymphocyte-to-monocyte ratio (LMR) has been suggested to be an important factor for predicting prognosis in patients with lung cancer, colon cancer and hematologic malignancies (18, 19). In a meta-analysis of adult solid tumors it was concluded that low pre-treatment LMR is an unfavorable prognostic factor (20).

In this study we investigated NLR and LMR in pediatric brain cancer patients on day of diagnosis before any treatment administration.

METHODS

Clinical data from pediatric brain cancer patients (M = malignant group) and elective pediatric patients hospitalized for hernia repair were retrospectively analyzed. Exclusion criteria were steroid treatment before the blood test and a history of concomitant diseases. Age, Sex, treatment, blood count plus differential were collected from blood tests performed before surgery in both groups. NLR, and the LMR were calculated and significance was determined by paired T-test. p < 0.05 was considered as statistically significant. ANOVA test was used to compare mean of NLR value in different brain tumor types.

RESULTS

Clinical data from 120 pediatric brain cancer patients and 171 elective pediatric patients hospitalized for hernia repair were retrospectively analyzed. The study was approved by the ethical review boards of both Sheba and Tel Aviv Sourasky Medical Centers and was consistent with the declaration of Helsinki. Cancer patients who received dexacort before the blood test were excluded. Children from the elective hernia surgery control group with known background diseases were also excluded. Ninety-nine cancer and 62 control patients that met the inclusion criteria and had all the data in the medical records were included in the analysis. Brain cancer patients consisted of 37 astrocytoma patients, 27 medulloblastoma patients, 25 patients with pilocytic astrocytoma, and 10 glioblastoma patients. Age, Sex, treatment, lymphocyte, Neutrophil count, and monocyte count were collected from routinely performed preoperative blood tests. NLR and the LMR were calculated and significance was determined by paired T-test. P < 0.05 was considered as statistically significant.

Male/female ratios in the study and control group were 64%/36% and 61%/29%, respectively. Mean age was 10.26 and 8.7 years old, respectively. No significant NLR and LMR differences were found between males and females in the patient group. Table 1 summarizes the blood count results, differential, NLR, and LMR in both groups.

The mean percentage of neutrophils was higher in the patient group (64.3%) compared to the control group (56.11%) p = 0.001. In contrast, the mean percentage of lymphocytes was significantly higher in the control group (32.08%) compared to the patient group (27.11%) p = 0.009. As a result, the NLR was significantly higher in the patient group (4.59) compared to the control group (2.96) p = 0.025. Although the mean percentage of monocytes was higher in the patient group (6.1%) compared to the control group (3.3%) p = 0.001, there was no significant difference in LMR between the patient group (5.3) compared to the control group (4.2) p = 0.08.

Table 2 summarizes the mean NLR results in different brain tumor types in children. Although NLR values of astrocytoma and pilocytic astrocytoma are lower than glioblastoma and medulloblastoma, no significant difference was found between the mean of NLR value in different tumor types by ANOVA test \(F = 3.75, p = 0.13\).

DISCUSSION

Pediatric cancers and especially solid tumors can have devastating effects on young lives and their families. There is increasing evidence that failures of the immune system may contribute to tumor development. Lymphocytes have an important role in tumor cells elimination. Neutrophils and macrophages contribute to tumor cell proliferation, and MDSC, which are found in high numbers in many tumors, may contribute to tumor development. Lymphocytes have an important role in tumor cells elimination.

### TABLE 1 | Blood count results, differential, NLR, and LMR in brain cancer and hernia groups.

| Parameter         | Brain cancer | SD | Hernia | SD | p-value |
|-------------------|--------------|----|--------|----|---------|
| White blood cells | 10.2 X 10^9/L| 5.3| 11.2X10^9/L| 10.9| 0.550 |
| Neutrophils       | 64.3%        | 16.5| 56.1% | 16.7| 0.001 |
| Lymphocytes       | 27.1%        | 14.3| 32.0% | 14.9| 0.009 |
| Monocytes         | 6.1%         | 2.9 | 3.3%  | 3.3 | 0.001 |
| NLR               | 4.5          | 5.4 | 2.9    | 3.4 | 0.025 |
| LMR               | 5.3          | 3.9 | 4.2    | 2.5 | 0.086 |

SD, Standard deviation.

### TABLE 2 | NLR value results in different brain tumor types in children.

| Tumor type         | N  | NLR |
|--------------------|----|-----|
| Astrocytoma        | 37 | 3.7 |
| Medulloblastoma     | 27 | 6.0 |
| Pilocytic astrocytoma | 25 | 3.3 |
| Glioblastoma       | 10 | 5.4 |

N, number of samples.
monocytes on the other hand, may promote tumor progression. In fact, suppression of the immune response to cancer cells is one of the impediments to develop effective immunotherapeutic approaches for glioma patients (21). Overcoming the suppression can be done by blocking the inhibitory signals of the immune system by anti CTLA4 and anti PD1/PDL1 therapy (22). On the other hand, persisting response of the inflammatory milieu paves the way to cancer (23). Neutrophils trigger and sustain a state of chronic inflammation (6) and high systematic immune-inflammation is significantly associated with a lower overall survival rate of patients with colon cancer (24), lung cancer (25), and breast cancer (26). Suppressing this arm of the immune response is necessary to limit proliferative signaling, angiogenesis, migration and invasion processes (2). Inhibitors of inflammatory pathways have been successful in pre-clinical tumor models and early clinical trials (27).

It has been shown that elevated NLR is predictive of poorer overall survival in patients with hepatocellular/squamous cell carcinoma, GBM (28–30), pancreatic ductal adenocarcinoma (31), ovarian cancer (32) and pediatric sarcoma (33). In addition, preoperative elevated NLR reflects a systemic inflammatory response and is a predictor of poor survival in gastric cancer (16). Finally, high NLR is associated with poorer outcomes in patients receiving immune checkpoint inhibitors (34). In our study, pediatric brain cancer patients’ blood samples present both increased neutrophil count and decreased lymphocyte count resulting in significantly higher NLR. Moreover, although no significant difference was found between the mean of NLR value in different tumor types in children, NLR values of astrocytoma and pilocytic astrocytoma are lower than glioblastoma and medulloblastoma. It is important to note that pediatric astrocytoma and pilocytic astrocytoma are with a more favorable prognosis compared to glioblastoma and medulloblastoma.

Using the body’s own immune system to fight cancer is increasingly desirable treatment for cancer because of its potential to specifically target the tumor while limiting damage to normal tissue. Because lymphocytes account for only 20–40% of the total WBC count, low levels of T cells may go unnoticed when WBC count is checked without a differential count of CD4+ (helper) T cells/CD8+ (suppressor) T cells/B cells. Reduced lymphocyte numbers may contribute to cancer development and may affect treatment, especially the current promising treatment of immunotherapy. Furthermore, the success of immunotherapy in tumors of the central nervous system depends on the immune microenvironment and lymphocyte tracking through the blood-brain barrier (BBB) into the central nervous system (35). The brain is presumably an immune-privileged organ due to the BBB (36). During gliomagenesis, the BBB is broken and circulating immune cells including T cells, B cells, macrophages, and MDSC cross the BBB (37). The resulting bi-directional communication between immune cells and glioma cells create an immunosuppressed microenvironment that promotes tumor survival and growth (38). Glioma-associated microglia and macrophages are attracted to the tumor (39) and can be polarized into M2 becoming tumor-supportive and immunosuppressive cells (40). The glioma immunosuppressive environment is further enhanced by elevated numbers of regulatory T cells (41). Immunophenotyping of pediatric brain tumors reveal immunosuppressive phenotype in higher grade tumors with more regulatory T cells present in these tumor types (42). Interestingly, it has been shown recently that intracranial tumors like GBM may cause depletion of mature T cells (43). The tumor imposed depletion of Sphingosine-1-phosphate receptor 1 from the T cell surface prevents their trafficking from lymphoid organs into the circulation. It may well be that in pediatric brain cancer patients the T cells are sequestered in the lymph nodes and can inversely be released to fight cancer by manipulations yet to be discovered. Thus, Immunotherapy via adoptive cell transfer, especially with T cells engineered to express chimeric antigen receptors, represents a promising approach (44). Recent evidence has demonstrated that systemic therapy for brain tumors is not limited by the BBB (45). Cellular therapy as well as reversing immune-suppression through immune checkpoint blockade are showing promising results for GBM (46). In light of these findings the prognostic as well as treatment response prediction value of the NLR warrants prospective validation in large cohorts of children with CNS tumors.

ETHICS STATEMENT

The study was retrospective study of clinical files. Clinical data from 120 pediatric brain cancer patients and 171 elective pediatric patients hospitalized for hernia repair were retrospectively analyzed. The study was approved by the ethical review boards of both Sheba and Tel Aviv Sourasky Medical Centers and was consistent with the declaration of Helsinki.

AUTHOR CONTRIBUTIONS

RM-S and DJ contributed to implementation, analysis, and interpretation of the data. RM-S, DJ, MY, AT, EF, and SC were involved in experimental design, in the writing of the manuscript, and have read and approved the final version.

REFERENCES

1. Grob ST, Levy JMM. Improving diagnostic and therapeutic outcomes in pediatric brain tumors. Mol Diagn Ther. (2018) 22:25–39. doi: 10.1007/s40291-017-0299-3
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013
3. Lee HJ, Hong CY, Kim MH, Lee YK, Nguyen-Pham TN, Park BC, et al. In vitro induction of anterior gradient-2–specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses as a potential therapy for colorectal cancer. Exp Mol Med. (2012) 44:60–7. doi: 10.3858/emm.2012.44.1.006
4. Thommen DS, Schumacher TN. T Cell dysfunction in cancer. Cancer Cell. (2018) 33:547–62. doi: 10.1016/j.ccell.2018.03.012
5. Coussens LM, Werb Z. Inflammation and cancer. Nature. (2002) 420:860–7. doi: 10.1038/nature01332
6. Rosales C. Neutrophil: a cell with many roles in inflammation or several cell types? Front Physiol. (2018) 9:113. doi: 10.3389/fphys.2018.00113
7. Schmidt H, Bastholt L, Geertsen P, Christensen JI, Larsen S, Gehl J, et al. Elevated neutrophil to lymphocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer. (2005) 93:273–8. doi: 10.1038/sj.bjc.6602702
8. Friddlender ZG, Albelda SM. Tumor-associated neutrophils: friend or foe? Carcinogenesis. (2012) 33:949–55. doi: 10.1093/carcin/bgs123
9. Aarts CEM, Kuipers TW. Neutrophils as myeloid-derived suppressor cells. Eur J Clin Invest. (2018) 48 (Suppl 2):e12989. doi: 10.1111/eci.12989
10. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol. (2005) 5:641–54. doi: 10.1038/nri1668
11. Habibi D, Jalili RB, Forouzandeh F, Ong CJ, Ghahary A. High expression of IMPACT protein promotes resistance to indoleamine 2,3-dioxygenase-induced cell death. J Cell Physiol. (2010) 225:196–205. doi: 10.1002/jcp.22220
12. Yuan XK, Zhao XK, Xia YC, Zhu X, Xiao P. Increased circulating immunosuppressive CD4+ (HLA-DR+/-) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma. J Int Med Res. (2011) 39:1381–91. doi: 10.1177/030006051103900424
13. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. (2009) 58:49–59. doi: 10.1007/s00262-008-0523-4
14. Leitch EF, Chakrabarti M, Crozier JE, McKee JE, Anderson JH, Horgan PG, et al. Comparison of the prognostic value of selected markers of the systemic inflammation-based neutrophil-lymphocyte ratio in patients with operable colon cancer: a retrospective study. Br J Cancer. (2009) 100:1266–70. doi: 10.1038/sj.bjc.6604027
15. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McClean DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. (2013) 88:218–30. doi: 10.1016/j.critrevonc.2013.03.010
16. Paramanathan A, Saxena A, Morris DL. A systematic review and meta-analysis on the impact of pre-operative neutrophil-lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol. (2014) 23:31–9. doi: 10.1016/j.suronc.2013.12.001
17. Templetson AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Yalon et al. NLR in Pediatric Brain Cancer
18. Tao MY, Wang ZH, Zhang MH, Ma TH, Yang XZ, Wu SN, et al. Neutrophil-to-lymphocyte ratio in prognosis of glioblastoma multiforme. J Neurooncol. (2018) 136:173–80. doi: 10.1007/s11060-017-2641-3
19. Mascarella MA, Mannard E, Silva SD, Zeitouni A. Neutrophil-to-lymphocyte ratio in head and neck cancer prognosis: a systematic review and meta-analysis. Head Neck. (2018) 40:1091–100. doi: 10.1002/hed.25075
20. Lopes M, Carvalho B, Vaz R, Linhares P. Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme. J Neurooncol. (2018) 18:357–65. doi: 10.1007/s11060-017-2641-3
21. Najjar M, Agrawal S, Emond JC, Halaunz KJ. Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma. J Hepatol Cell Carcinoma. (2018) 5:17–28. doi: 10.2147/JHC.S87692
22. Abe T, Nakata K, Kibe S, Mori Y, Miyasaka Y, Ohuchida K, et al. Prognostic value of preoperative nutritional and immunological factors in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol. (2015) 22:4003–4009. doi: 10.1245/s10434-015-4761-6
23. Yang Z, Gou JH, Guo CS, Li XH, Yang WC. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: a systematic review and meta-analysis of observational studies. Oncotarget. (2017) 8:164641–24. doi: 10.18632/oncotarget.16793
24. Vasquez L, Leon E, Beltran B, Maza I, Oscanoa M, Geronimo JJ, Pretreatment neutrophil-to-lymphocyte ratio and lymphocyte recovery: independent prognostic factors for survival in pediatric sarcomas. J Pediatr Hematol Oncol. (2017) 39:538–46. doi: 10.1097/MPH.0000000000000911
25. Sacdal DB, Lucero JA, Sacdal DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther. (2018) 11:955–65. doi: 10.2147/OTT.S153290
26. Ameratunga M, Coleman N, Welsh L, Saran F, Lopez J. CNS cancer immunity cycle and strategies to target this for glioblastoma. Oncotarget. (2018) 9:22802–16. doi: 10.18632/oncotarget.24896
27. Wilson EH, Weningger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest. (2011) 120:1368–79. doi: 10.1172/JCI41911
28. Gieryng A, Paszczolowska D, Walentynowicz KA, Rajan WD, Kaminska B. Immune microenvironment of gliomas. Lab Invest. (2017) 97:498–518. doi: 10.1038/labinvest.2017.19
29. Galvao RP, Zong H. Inflammation and gliomagenesis: bi-directional communication at early and late stages of tumor progression. Curr Pathobiol Rep. (2013) 1:19–28. doi: 10.3892/cpr.2013.457
30. Okada M, Saio M, Kito Y, Ohe N, Yano H, Yoshimura S, et al. Tumor-associated macrophage/microglia infiltration in human gliomas is correlated with MCP-3, but not MCP-1. Int J Oncol. (2009) 34:1621–7. doi: 10.3892/ijo_00000292
31. Wu SY, Watabe K. The roles of microglia/macrophages in tumor progression of brain cancer and metastatic disease. Front Biosci. (2017) 22:1805–29. doi: 10.2741/4573
32. El Andalousi A, Lesniak MS. CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol. (2007) 83:145–52. doi: 10.1007/s11060-006-9314-y
33. Plant AS, Koyama S, Shiomi K, Itoh M, Higashiyama Y, Ligon KL, et al. Immune phenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. J Neurooncol. (2018) 143:269–78. doi: 10.1007/s11060-017-2739-9
34. Chongsathidkit P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. (2018) 24:1459–68. doi: 10.1038/s41591-018-0135-2
44. Choi BD, Maus MV, June CH, Sampson JH. Immunotherapy for glioblastoma: adoptive T-cell strategies. *Clin Cancer Res.* (2019). 25:2042–8. doi: 10.1158/1078-0432.CCR-18-1625

45. Zhang I, Formenti SC, Kaisely JPS. Immunotherapy plus stereotactic radiosurgery: building on the promise of precision medicine for CNS malignancies-PART 1: principles of combined treatment. *Oncology.* (2018) 32:e28–e32. Online available at: https://www.cancernetwork.com/oncology-journal/immunotherapy-plus-stereotactic-radiosurgery-building-promise-precision-medicine-cns-malignancies

46. Neagu MR, Reardon DA. An update on the role of immunotherapy and vaccine strategies for primary brain tumors. *Curr Treat Options Oncol.* (2015) 16:54. doi: 10.1007/s11864-015-0371-3

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Yalon, Toren, Jabarin, Fadida, Constantini and Mehrian-Shai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.